Woolly mammoths & Tasmanian tigers & dodo birds, oh my! Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and two other extinct species, has raised a $200 million Series C at a $10.2 billion valuation from TWG Global. The funding comes two years after the company closed its previous round at a reported valuation of $1.5 billion. Why did investors pour so much capital at an eye-popping valuation for a company that has yet to generate any revenue and whose flagship projects, resurrecting an extinct mammoth and Tasmanian tiger, are not expected to be completed until 2028? The company claims it has made significant breakthroughs on all three of its main projects, which, in addition to the mammoth and the Tasmanian tiger (also known as the thylacine), includes the dodo bird, and is on schedule or even ahead of it to resurrect these animals. Read more on Colossal Biosciences at the link in the bio 👆 Article by Marina Temkin Image Credits: LEONELLO CALVETTI/SCIENCE PHOTO LIBRARY / Getty Images #TechCrunch #technews #artificialintelligence #biotech #startup #founder #venturecapital #funding